PMID- 37510374
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230731
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 14
IP  - 7
DP  - 2023 Jul 19
TI  - Associations of HLA Polymorphisms with Chronic Kidney Disease in Japanese 
      Rheumatoid Arthritis Patients.
LID - 10.3390/genes14071470 [doi]
LID - 1470
AB  - OBJECTIVES: The prevalence of chronic kidney disease (CKD) was reported to be 
      higher in rheumatoid arthritis (RA) patients than in normal healthy individuals. 
      Human leukocyte antigen (HLA) was associated with RA or CKD. Few studies on the 
      association of HLA with CKD in RA have been reported. Here, we investigated the 
      association of HLA polymorphisms with CKD in Japanese RA patients. METHODS: 
      HLA-DRB1 genotyping was conducted in 351 Japanese RA patients with CKD (estimated 
      glomerular filtration rate [eGFR] lower than 60 [mL/min/1.73 m(2)]) and 959 
      without CKD (eGFR equal to or higher than 60 [mL/min/1.73 m(2)]). Associations of 
      allele carrier frequencies of DRB1 with CKD were examined in the RA patients. 
      RESULTS: There was an association of DRB1*13:02 with CKD in RA, but this did not 
      achieve statistical significance (p = 0.0265, odds ratio [OR] 1.70, pc = 0.7412, 
      95% confidence interval [CI] 1.09-2.64). The DR6 serological group was associated 
      with CKD in RA (p = 0.0008, OR 1.65, 95% CI 1.24-2.20). A gene-dosage effect of 
      DR6 was not detected. Logistic regression analysis showed that the association of 
      DR6 with CKD in RA was independent of clinical characteristics. CONCLUSIONS: The 
      present study first revealed the independent predisposing association of DR6 with 
      CKD in Japanese RA patients, although DR6 is known to be protective against RA. 
      Our data suggest direct or indirect roles of HLA for the development of CKD in 
      RA, but the mechanisms are not clear.
FAU - Higuchi, Takashi
AU  - Higuchi T
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
AD  - Department of Nephrology, Ushiku Aiwa General Hospital, 896 Shishiko-cho, Ushiku 
      300-1296, Japan.
FAU - Oka, Shomi
AU  - Oka S
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
FAU - Furukawa, Hiroshi
AU  - Furukawa H
AUID- ORCID: 0000-0003-1353-8056
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
FAU - Shimada, Kota
AU  - Shimada K
AD  - Department of Rheumatology, National Hospital Organization Sagamihara National 
      Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan.
AD  - Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2-8-29 
      Musashi-dai, Fuchu 183-8524, Japan.
FAU - Hashimoto, Atsushi
AU  - Hashimoto A
AD  - Department of Rheumatology, National Hospital Organization Sagamihara National 
      Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan.
AD  - Department of Internal Medicine, Sagami Seikyou Hospital, 6-2-11 Sagamiohno, 
      Minami-ku, Sagamihara 252-0303, Japan.
FAU - Komiya, Akiko
AU  - Komiya A
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
AD  - Department of Clinical Laboratory, National Hospital Organization Sagamihara 
      National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan.
FAU - Matsui, Toshihiro
AU  - Matsui T
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
AD  - Department of Rheumatology, National Hospital Organization Sagamihara National 
      Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 252-0392, Japan.
FAU - Fukui, Naoshi
AU  - Fukui N
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
AD  - Department of Life Sciences, Graduate School of Arts and Sciences, The University 
      of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan.
FAU - Tohma, Shigeto
AU  - Tohma S
AD  - Department of Rheumatology, National Hospital Organization Tokyo National 
      Hospital, 3-1-1 Takeoka, Kiyose 204-8585, Japan.
AD  - Clinical Research Center for Allergy and Rheumatology, National Hospital 
      Organization Sagamihara National Hospital, 18-1 Sakuradai, Minami-ku, Sagamihara 
      252-0392, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230719
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - Humans
MH  - East Asian People
MH  - Genetic Predisposition to Disease
MH  - *Arthritis, Rheumatoid/complications/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - *Renal Insufficiency, Chronic/genetics
PMC - PMC10379419
OTO - NOTNLM
OT  - HLA
OT  - chronic kidney disease
OT  - rheumatoid arthritis
COIS- H.F. has the following conflicts, and the following funders are supported wholly 
      or in part by the indicated pharmaceutical companies. The Japan Research 
      Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science 
      Foundation is supported by an endowment from Takeda Pharmaceutical Company, and 
      the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The 
      Daiwa Securities Health Foundation was established by Daiwa Securities Group, 
      Inc., and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui 
      Sumitomo Insurance Co., Ltd. H.F. was supported by research grants from 
      Bristol-Myers Squibb Co. H.F. received honoraria from Ajinomoto Co., Inc., 
      Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan, 
      Inc., and Takeda Pharmaceutical Company, Luminex Japan Corporation, Ltd., and 
      Ayumi Pharmaceutical Corporation. T.M. was supported by research grants from 
      AbbVie Japan Co., Ltd., Asahi Kasei Pharma, Astellas Pharma, Inc., Chugai 
      Pharmaceutical Co., Ltd., Eisai Co., Ltd., Pfizer, Inc., Mitsubishi-Tanabe Pharma 
      Co., and Taisho Pharmaceutical Co., Ltd. T.M. received honoraria from AbbVie 
      Japan Co., Ltd., Asahi Kasei Pharma, Astellas Pharma, Inc., Chugai Pharmaceutical 
      Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., 
      Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer, Inc., Takeda 
      Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. S.T. was supported by research 
      grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas 
      Pharma, Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe 
      Pharma Corporation, Merck Sharp and Dohme, Inc., Pfizer Japan, Inc., Takeda 
      Pharmaceutical Company Limited, and Teijin Pharma Limited. S.T. received 
      honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma, Inc., AbbVie GK, 
      Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe 
      Pharma Corporation, and Pfizer Japan, Inc. The other authors declare no financial 
      or commercial conflicts of interest.
EDAT- 2023/07/29 11:47
MHDA- 2023/07/31 06:42
PMCR- 2023/07/19
CRDT- 2023/07/29 01:17
PHST- 2023/06/24 00:00 [received]
PHST- 2023/07/14 00:00 [revised]
PHST- 2023/07/18 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/29 11:47 [pubmed]
PHST- 2023/07/29 01:17 [entrez]
PHST- 2023/07/19 00:00 [pmc-release]
AID - genes14071470 [pii]
AID - genes-14-01470 [pii]
AID - 10.3390/genes14071470 [doi]
PST - epublish
SO  - Genes (Basel). 2023 Jul 19;14(7):1470. doi: 10.3390/genes14071470.